Zydus Life rises on USFDA nod for schizophrenia drug 0 12.09.2022 11:48 Business Standard Zydus Lifesciences rose 1.51% to Rs 380 after Cadila Healthcare, U.S. subsidiary of the company has received final approval from the USFDA to market Cariprazine capsules. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
